Effect of arterial hypertension on quality of life and anxiety in middle-aged patients with breast cancer

Abstract

BACKGROUND: Arterial hypertension is one of the key risk factors for the development of cardiotoxicity in cancer patients. The importance for patients with left breast cancer is due to the possibility of the heart getting into the radiation area during treatment. The use of a method for assessing the quality of life and symptoms of anxiety can help improve treatment in such patients by increasing the interaction between a physician and a patient.

AIM: The aim of the study is to assess the quality of life and the level of anxiety in patients with breast cancer, depending on the presence of arterial hypertension.

MATERIALS AND METHODS: 67 patients with HER2neu negative cancer of the left breast have been examined. The average age is 42 (47; 63). All the patients after radical mastectomy and a course of chemotherapy with the inclusion of doxorubicin in a cumulative dose of no more than 360 mg/m² have been hospitalized for 3D conformal radiation therapy. The first group included 32 patients with grade I–II comorbid hypertension; the second group included 35 patients without hypertension. The examination included an assessment of the status of an oncological patient according to the ECOG scale, echocardiography with an assessment of diastolic function, determination of the level of reactive and personal anxiety according to the Spielberger – Khanin scale and quality of life using the SF-36 questionnaire.

RESULTS: In the group of the patients with combined hypertension, left ventricular hypertrophy has been detected in 48 % of cases. In the patients of both groups with preserved ejection fraction, type I diastolic dysfunction has been detected (E/A < 1): in the patients of the first group — in 59.4 % of cases, in the patients of the second — 31.4 % of cases. The difference obtained is due to the effect of hypertension on the left ventricular relaxation disorder. The level of reactive anxiety was significantly higher in the patients of the first group and amounted to 43.8 (41.2; 46.2) versus 38.4 (32.7; 42.6) points in the second group. The level of personal anxiety was high in the patients of both groups, which can be explained by the predominant influence of cancer. In the patients of both groups, there was a decrease in indicators according to the SF-36 questionnaire on all scales. The most significant changes have been obtained on the scales of physical functioning, role-based physical functioning, pain, vitality and general health. Cancer patients with concomitant hypertension rated their health status lower, while they are more likely to note a decrease in daily role activity as a result of their emotional state.

CONCLUSIONS: The data obtained indicate that arterial hypertension has a significant negative effect on the level of reactive anxiety and quality of life indicators of breast cancer patients, which is of great importance in the formation of a patient-oriented approach to the therapeutic support of specific treatment in such patients.

Keywords

hypertension / breast cancer / quality of life / anxiety

References

[1] Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: Esmo consensus recommendations. Ann Oncol. 2020;31(2):171–190. DOI: 10.1016/j.annonc.2019.10.023

[2] Curigliano G., Lenihan D., Fradley M. et al. Management of cardiac disease in cancer patients throughout oncological treatment: Esmo consensus recommendations // Ann. Oncol. 2020. Vol. 31, No. 2. P. 171–190. DOI: 10.1016/j.annonc.2019.10.023

[3] Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960. DOI: 10.1002/ejhf.1920

[4] Lyon A.R., Dent S., Stanway S. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society // Eur. J. Heart Fail. 2020. Vol. 22, No. 11. P. 1945–1960. DOI: 10.1002/ejhf.1920

[5] Zamorano JL, Lancellotti P, Rodrigues Munoz D, et al. 2016 ESC Position Paper on cancer treatment and cardiovascular toxity developed under the auspices of the ESC Committee for Practice Guedlines: The Task Force for cancer treatment and cardiovascular toxity of the Europen Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801. DOI: 10.1093/eurheartj/ehw211

[6] Zamorano J.L., Lancellotti P., Rodrigues Munoz D. et al. 2016 ESC Position Paper on cancer treatment and cardiovascular toxity developed under the auspices of the ESC Committee for Practice Guedlines: The Task Force for cancer treatment and cardiovascular toxity of the Europen Society of Cardiology (ESC) // Eur. Heart J. 2016. Vol. 37, No. 36. P. 2768–2801. DOI: 10.1093/eurheartj/ehw211

[7] Cardinale D, Colombo A, Lamantia G, et al. Anthracycline induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010. Vol. 55, No. 3. P. 213–220. DOI: 10.1016/j.jacc.2009.03.095

[8] Cardinale D., Colombo A., Lamantia G. et al. Anthracycline induced cardiomyopathy: clinical relevance and response to pharmacologic therapy // J. Am. Coll. Cardiol. 2010. Vol. 55, No. 3. P. 213–220. DOI: 10.1016/j.jacc.2009.03.095

[9] Cardinale D, Stivata F, Cipolla CM. Oncologic therapies associated with cardiac toxicities: how to minimize the risks. Expert Rev Anticancer Ther. 2019;19(5):359–374. DOI: 10.1080/14737140.2019.1596804

[10] Cardinale D., Stivata F., Cipolla C.M. Oncologic therapies associated with cardiac toxicities: how to minimize the risks // Expert. Rev. Anticancer Ther. 2019. Vol. 19, No. 5. P. 359–374. DOI: 10.1080/14737140.2019.1596804

[11] Mistiaen WP. Cancer in heart disease patients: what are the limitations in the treatment strategy? Future Cardiol. 2013;9(4):535–547. DOI: 10.2217/fca.13.33

[12] Mistiaen W.P. Cancer in heart disease patients: what are the limitations in the treatment strategy? // Future Cardiol. 2013. Vol. 9, No. 4. P. 535–547. DOI: 10.2217/fca.13.33

[13] Vologdina IV, Zhabina RM, Korytova LI, et al. Cardiovascular complications in oncological patients at stage of chemoradiotherapy: actual position of the problem. Problems in Oncology. 2018;64(4):470–477. (In Russ.)

[14] Вологдина И.В., Жабина Р.М., Корытова Л.И. и др. Кардиоваскулярные осложнения у онкологических больных на этапе проведения химиолучевой терапии: современное состояние проблемы // Вопросы онкологии. 2018. Т. 64, № 4. С. 470–477.

[15] Ionova TI, Nikitina TP, Novik AA, Snegovoj AV. Prakticheskie rekomendacii po ocenke kachestva zhizni u onkologicheskih bol’nyh. Malignant Tumoursis. 2017;7(3S2):586–591. (In Russ.). DOI: 10.18027/2224-5057-20l7-7-3s2-586-59l

[16] Ионова Т.И., Никитина Т.П., Новик А.А., Снеговой А.В. Практические рекомендации по оценке качества жизни у онкологических больных // Злокачественные опухоли. 2017. Т. 7, № 3S2. С. 586–591. DOI: 10.18027/2224-5057-20l7-7-3s2-586-59l

[17] Fedorets VN, Vologdina IV, Poroshina EG, Simonova ON. Psychosomatic features of patients of an old age with ischemic heart disease complicated by chronic heart failure. Herald of North Western State Medical University named after I.I. Mechnikov. 2008;(4(29)):92–96. (In Russ.)

[18] Федорец В.Н., Вологдина И.В., Порошина Е.Г., Симонова О.Н. Психосоматические особенности пациентов старческого возраста с ИБС, осложненной хронической сердечной недостаточностью // Вестник Санкт-Петербургской государственной медицинской академии им. И.И. Мечникова. 2008. № 4(29). С. 92–96.

[19] Vologdina I, Poroshina E, Rozov A, Simonova O. Combined therapy in old patiens with coronary heart disease and arterial hypertension. Vrach. 2009;(4):26–30. (In Russ.)

[20] Вологдина И., Порошина Е., Розов А., Симонова О. Комбинированная терапия больных старческого возраста с ишемической болезнью сердца и артериальной гипертензией // Врач. 2009. Т.4. С. 26–30.

[21] Vologdina IV, Simanenkov VI, Poroshina EG, Min’ko BA. Quality of life and adherence in patients with heart failure, cognitive and affective impairment. Herald of North Western State Medical University named after I.I. Mechnikov. 2016;8(1):45–49. (In Russ.)

[22] Вологдина И.В., Симаненков В.И., Порошина Е.Г., Минько Б.А. Качество жизни и приверженность терапии у пациентов пожилого и старческого возраста с хронической сердечной недостаточностью, коморбидными когнитивными и аффективными нарушениями // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2016. Т. 8, № 1. С. 45–49.

[23] Kolandaivelu K, Leiden BB, O’Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J. 2014;35(46):3267–3276. DOI: 10.1093/eurheartj/ehu364

[24] Kolandaivelu K., Leiden B.B., O’Gara P.T., Bhatt D.L. Non-adherence to cardiovascular medications // Eur. Heart J. 2014. Vol. 35, No. 46. P. 3267–3276. DOI: 10.1093/eurheartj/ehu364

[25] Larsen СМ, Mulvagh SL. Cardio-oncology: what you need to know now for clinical practice and echocardiography. Echo Res Pract. 2017;4(1):R33–R41. DOI: 10.1530/ERP-17-0013

[26] Larsen С.М., Mulvagh S.L. Cardio-oncology: what you need to know now for clinical practice and echocardiography // Echo Res. Pract. 2017. Vol. 4, No. 1. R33–R41. DOI: 10.1530/ERP-17-0013

[27] Poroshina EG, Vologdina IV, Pestereva EV. Psychological characteristics and quality of life of cancer patients with concomitant cardiovascular pathology. Herald of North Western State Medical University named after I.I. Mechnikov. 2017;9(1):83–89. (In Russ.). DOI: 10.17816/mechnikov20179183-88

[28] Порошина Е.Г., Вологдина И.В., Пестерева Е.В. Психологические особенности и качество жизни у онкологических больных с сочетанной сердечно-сосудистой патологией // Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2017. Т. 9, № 1. С. 83−89. DOI: 10.17816/mechnikov20179183-88

[29] Iwarmitsu Y, Shimoda K, Abe H, et al. Anxiety, emotional suppression and psychological distress before and after breast cancer diagnosis. Psychosomatics. 2005;46(1):19–24. DOI: 10.1176/appi.psy.46.1.19

[30] Iwarmitsu Y., Shimoda K., Abe H. et al. Anxiety, emotional suppression and psychological distress before and after breast cancer diagnosis // Psychosomatics. 2005. Vol. 46, No. 1. P. 19–24. DOI: 10.1176/appi.psy.46.1.19

[31] Wu SP, Hsu YC. The relationship between coping behaviors and symptom distress in elderly patients with cancer undergoing initial chemotherapy. Hu Li Za Zhi. 2016;63(6):30–40. (In Chinese). DOI: 10.6224/JN.63.6.30

[32] Wu S.P., Hsu Y.C. The relationship between coping behaviors and symptom distress in elderly patients with cancer undergoing initial chemotherapy // Hu Li Za Zhi. 2016. Vol. 63, No. 6. P. 30–40. (In Chinese). DOI: 10.6224/JN.63.6.30

RIGHTS & PERMISSIONS

Poroshina E.G., Vologdina I.V., Zhabina R.M., Krasilnikova L.A.